professor timothy hughes

(2016). Roberts, M., Dyson, P., Rawling, C., Thorp, D., Rawling, T., White, D., . . Hochhaus, A. . . Eadie, L., Hughes, T., & White, D. (2010). Donor leukocyte infusions for chronic myeloid leukemia in relapse after allogeneic bone marrow transplantation [3]. . Dr. Timothy Hughes, PsyD, MA, Psychologist, New York, NY, 10010, (646) 679-7299, Looking for a therapist may seem like a daunting task, but … Proton pump inhibitors significantly increase the intracellular concentration of nilotinib, but not imatinib in target CML cells. Taylor, K. (2007). Watch Dr. Timothy Hughes, a leading expert in hematology, as he discusses the evolving treatment goals and therapeutic options in chronic myelogenous leukemia (CML). Integrative Genomics Reveals Cancer Associated Mutations Are Common at Diagnosis of CML in Patients with Poor Response to TKI Therapy. In, Mahon, F. -X., Boquimpani, C., Takahashi, N., Benyamini, N., Clementino, N. C. D., Shuvaev, V., . Parker, M. (2018). Dasatinib (Sprycel (TM)) Inhibits Oteoclast Activity in Vitro and in Vivo Via a C-Fms-Dependent and C-Src-Independent Mechanism. Living with CML: Is death no longer the end (point)?. Colloidally stabilized magnetic carbon nanotubes providing MRI contrast in mouse liver tumors. Fawcett, A. S., Hughes, T. C., Zepeda-Velazquez, L., & Brook, M. A. . Lv, Y., Hughes, T., Hao, X., Mei, D., & Tan, T. (2011). . White, D. L. (2016). Hughes, A., Clarson, J., White, D. L., Yeung, D. T., Hughes, T. P., & Yong, A. right to recover all costs incurred in the event of breach of this . le Coutre, P., Cortes, J., Kim, D. -W., Pinilla-Ibarz, J., Paquette, R., Chuah, C., . . Branford, S. (2014). . Parker, W., Ho, M., Scott, H., Hughes, T., & Branford, S. (2012). . Chronic Myeloid Leukemia Patients with Deep Molecular Responses to Tyrosine Kinase Inhibitors Have Increased Effector Natural Killer and Cytotoxic T Cell Immune Responses to Leukaemia-Associated Antigens and Concomitant Reduced Immune Suppressors. Pagani, I. S., Kok, C., Saunders, V., Schwarer, A., Hughes, T. P., White, D. L., & Ross, D. M. (2018). In M. Kizaki (Ed.). Professor Hughes's Top Tags. . Frost, M., Ferrao, P., Hughes, T., & Ashman, L. (2002). ASXL1 and BIM germ line variants predict response and identify CML patients with the greatest risk of imatinib failure. In, Yeung, D., Osborn, M., White, D., Branford, S., Haswell, L., Slader, C., . . Morley, A. In, Cortes, J. E., Hochhaus, A., Kantarjian, H. M., Guilhot, F., Kota, V. K., Hughes, T. P., . Hiwase, D., White, D., Saunders, V., Kumar, S., Melo, J., & Hughes, T. (2009). . . We acknowledge and recognise this in everything we do. Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily. Wellcome Trust Principal Research Fellow; Research Group - CV - Google Scholar If you are interested in doing a PhD with me, the best route is through one of Oxford's (or UCL's) funded schemes. Lipton, J. H. (2015). Hiwase, D., Yeung, D., Carne, L., Ross, D., Grigg, A., & Hughes, T. (2013). (2017). . White, D. L. (2018). . In, Pasquini, R., Cortes, J., Kantarjian, H. M., Joske, D., Meillon, L. A., Mongay, L., . False-positive results with PCR to detect leukaemia-specific transcript. Peripheral blood is a source of BCR-ABL-negative pre-progenitors in early chronic phase chronic myeloid leukemia.. Collins, D. J., Hughes, T. C., & Johnson, W. M. (1996). Ponatinib efficacy and safety in heavily pretreated leukemia patients (Pts) in the PACE trial at 3 years. Sweeney, D. F. (2004). le Coutre, P., Hughes, T., Mahon, F., Kim, D., Steegmann, J., Shah, N., . . Hughes, T. P., & Branford, S. (2009). . . In, Eadie, L. N., Saunders, V. A., Leclercq, T. M., Branford, S., White, D. L., & Hughes, T. P. (2015). Assistant Professor, Gerontology and Geriatric Medicine; Research Interests. In, Shah, N. P., Kantarjian, H. M., Kim, D. W., Réa, D., Dorlhiac-Llacer, P. E., Milone, J. H., . Grigg, A. Irani, Y. D., Hughes, A., Clarson, J., Kok, C. H., Shanmuganathan, N., White, D. L., . (2017). In, Tan, K. J., Moad, G., Turner, K. A., Polyzos, A., Hughes, T. C., Hutt, O. E., & Hao, X. Faculty of Natural Sciences , Department of Physics. Understanding how these drugs work in synergy will enhance our ability to predict whether patients are likely to respond to combination therapy, and clarify ways to maximise synergism between these agents. Comparison of genomic and reverse transcriptase Q-PCR for the monitoring of first-line imatinib treatment: an ALLG CML9 sub-study. Schafranek, L., Nievergall, E., Powell, J. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. Cortes, J., Kim, D., Pinilla-Ibarz, J., le Coutre, P., Paquette, R., Chuah, C., . International Randomized Study of Interferon Vs STI571 (IRIS) 8-Year Follow up: Sustained Survival and Low Risk for Progression or Events in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Imatinib.. Discuss the professor’s professional abilities including teaching style and ability to convey the material clearly. . Kantarjian, H. (2010). . Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations. Branford, S. (2010). . . Deininger, M. W., Cortes, J. E., Kim, D. -W., Nicolini, F. E., Talpaz, M., Baccarani, M., . In, Cortes, J. E., Pinilla-Ibarz, J., Le Coutre, P. D., Paquette, R., Chuah, C., Nicolini, F. E., . Sudden blast crisis in chronic myeloid leukemia treated with tyrosine kinase inhibitors. (1989). . Ziebarth, N. (2008). . Upfront Imatinib with Selective Early Switching to Nilotinib Leads to Excellent Achievement of Deep Molecular Response in Chronic Phase CML: 5 Year (Final) Analysis of the TIDEL-II Study. . To facilitate these activities, entries in the University Phone Directory are not limited to University employees. Professor Timothy Hughes The information in this directory is provided to support the academic, administrative and business activities of the University of Adelaide. . Myeloid leukaemia treatment and survival - the south australian experience, 1977 to 2002. Short-Term Intense Bcr-Abl Kinase Inhibition Is Adequate to Trigger Cell Death in CML Cell Lines but Not in CML-CD34+Cells Unless They Are Growth Factor Deprived. Vandyke, K., Fitter, S., Drew, J., Fukumoto, S., Schultz, C., Sims, N., . Larson, R. (2011). Cervantes, F. (2014). Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. (2012). Hochhaus, A. Hehlmann, R. (2006). A perfluoropolyether corneal inlay for the correction of refractive error. . Cross, N. C. P., Hughes, T. P., Feng, L., O'Shea, P., Bungey, J., Marks, D. I., . The role of alternative splicing patterns of BCR/ABL transcripts in the generation of the blast crisis of chronic myeloid leukaemia. Shanmuganathan, N., & Hughes, T. (2020). . Pagani, I. S., Dang, P., Saunders, V. A., Braley, J., Thieleke, A., Branford, S., . . . . Melo, J. V., Hughes, T. P., & Apperley, J. F. (2003). Azobenzene moiety variation directing self-assembly and photoresponsive behavior of azo-surfactants. . Mike O'Connor. Professor Banting and Best Department of Medical Research University of Toronto 160 College St. Room 1302 Toronto, ON, M5S 3E1 Canada . Ross, D., O'Hely, M., Bartley, P., Dang, P., Score, J., Goyne, J., . Professor Timothy Hughes, the University of Adelaide Beat Cancer Professor and Cancer Theme Leader at the South Australian Health and Medical Research Institute (SAHMRI), says that treatments such as chemotherapy with take a back seat to targeted therapies. In, Branford, S., Wang, P., Yeung, D., Purins, A., Marum, J. E., Nataren, N., . Kantarjian, H. M. (2012). Sawyers, C. (2005). . Nieborowska-Skorska, M., Kopinski, P., Ray, R., Hoser, G., Ngaba, D., Flis, S., . (2010). White, D. L., Saunders, V., Yeung, D., Grigg, A., & Hughes, T. (2012). Khoury, H., Guilhot, F., Hughes, T., Kim, D., & Cortes, J. Hood, L. (1994). A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. (2009). Professor Timothy Hughes. Shah, N. P. (2007). Wilkie, J. . . . . Detection of minimal residual disease in an AML patient with trisomy 8 using interphase fish. A novel somatic JAK2 kinase-domain mutation in pediatric acute lymphoblastic leukemia with rapid on-treatment development of LOH. It is estimated that approximately 50% of CML patients may be eligible to stop TKIs, however half of them experience molecular relapse, usually within 6 months, and have to restart therapy. Efficacy and Safety of Nilotinib In Chronic Phase (CP) Chrome Myeloid Leukemia (CML) Patients (Pts) with Type 2 Diabetes In the ENESTnd Trial. Detection and significance of minimal residual disease in patients with leukaemia and lymphoma. Preparation of monomeric and polymeric β-cyclodextrin functionalized monoliths for rapid isolation and purification of puerarin from Radix puerariae. (2013). Eadie, L., Hughes, T., & White, D. (2014). . Assistant Professor, Gerontology and Geriatric Medicine; Timothy Hughes, PhD. In, Parker, W. T., Ho, M., Scott, H. S., Hughes, T. P., & Branford, S. (2011). Cortes, J., Goldman, J. M., & Hughes, T. (2012). Mueller, M. C. (2017). BCR-ABL transcript analysis of patients (pts) with imatinib-resistant or -intolerant chronic myeloid leukemia in chronic phase (CML-CP) treated with nilotinib.. Larson, R., le Coutre, P., Reiffers, J., Hughes, T., Saglio, G., Edrich, P., . (2013). Therapeutic concentrations of dasatinib inhibit in vitro osteoclastogenesis. Deininger, M. W., Cortes, J. E., Kim, D. -W., Nicolini, F. E., Talpaz, M., Baccarani, M., . Hughes, T. (2008). (2013). Collins, D. J., Hughes, T. C., & Johnson, W. M. (1999). In, Hughes, T. P., Munhoz, E. C., Elhaddad, A., Chuan, O. T., Abdulkadyrov, K., Shortt, J., . Tvorogov, D., Thomas, D., Liau, N. P. D., Dottore, M., Barry, E. F., Lathi, M., . He and his wife, Ba From Nanodroplets by the ouzo effect to interfacial nanolenses. Timothy Hughes , Ph.D. Hiwase, D., Tan, P., D'Rozario, J., Taper, J., Powell, A., Irving, I., . . White, H., Hedges, J., Bendit, I., Branford, S., Colomer, D., Hochhaus, A., . In, Hiwase, D., & Hughes, T. (2008). Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. Evans, M. D. M., McLean, K. M., Hughes, T. C., & Sweeney, D. F. (2001). Hughes, T. (2018). Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive value. In, Engler, J. R., Frede, A., Saunders, V. A., Zannettino, A. C. W., White, D. L., & Hughes, T. P. (2009). . . . . Limited clinical value of regular bone marrow cytogenetic analysis in imatinib-treated chronic phase CML patients monitored by RQ-PCR for BCR-ABL. Hughes, T. P. (2019). . Hughes, T. (2002). . Hochhaus, A., & Hughes, T. (2004). Contrasting response of patients with chronic myeloid leukaemia (CML) and the highly imatinib resistant L248V mutation that may be related to an increased propensity of some patients to form an associated deletion mutant with increased imatinib sensitivity. Long-term corneal biocompatibility of PFPE for an implantable contact lens. Bone marrow fibrosis associated with long-term imatinib therapy: resolution after switching to a second-generation TKI. Dr. Timothy Hughes specializes in Otolaryngology (ENT) and is part of AMITA Health's extensive provider network, which includes more than 7,000 affiliated providers. . Significance of residual leukaemia transcripts after bone marrow transplant for CML. Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia. Parker, W., Lawrence, R., Ho, M., Irwin, D., Scott, H., Hughes, T., & Branford, S. (2011). See the complete profile on LinkedIn and discover Timothy’s connections and jobs at similar companies. Hughes, T. (2006). . . Hochhaus, A. Vandyke, K., Fitter, S., Dewar, A., Hughes, T., & Zannettino, A. In, Branford, S., Rudzki, Z., Miller, B., Grigg, A., Seymour, J., Schwarer, A., . In, Lipton, J. H., Chuah, C., Guerci-Bresler, A., Rosti, G., Simpson, D., Lustgarten, S., . Sadras, T., Heatley, S., Kok, C., Quek, K., Dang, P., Nievergall, E., . Nievergall, E., Reynolds, J., Kok, C., Watkins, D., Biondo, M., Busfield, S., . Ultrafast fabrication of covalently cross-linked multifunctional graphene oxide monoliths. . Hughes, T., Janssen, J. W. G., Morgan, G., Martiat, P., Saglio, G., Pignon, J. M., . Branford, S., Ross, D., Prime, J., Field, C., Altamura, H., Yeoman, A., . Timothy Hughes , Ph.D. . McLean, K. (2004). Enhancing thermal stability and mechanical properties of lyotropic liquid crystals through incorporation of a polymerizable surfactant. . Evolving concepts in the management of chronic myeloid leukemia: Recommendations from an expert panel on behalf of the European LeukemiaNet. Low incidence of peripheral arterial disease in patients receiving dasatinib in clinical trials. . Hughes, T. (2018). In, Ross, D. M., Hughes, T. P., & Branford, S. (2006). OCT1 and imatinib transport in CML: Is it clinically relevant?. . Dasatinib or high-dose Imatinib for chronic-phase chronic myeloid leukemia resistant to Imatinib at a dose of 400 to 600 milligrams daily. Zhang, Z., Hao, X., Gurr, P. A., Blencowe, A., Hughes, T. C., & Qiao, G. G. (2012). Ross, D. M. (2018). . Oral versus intravenous ganciclovir for the prophylaxis of cytomegalovirus disease after allogeneic bone marrow transplantation. . See the complete profile on LinkedIn and discover Timothy’s connections and jobs at similar companies. by Steinbach and Debatin. Potential mechanisms of disease progression and management of advanced-phase chronic myeloid leukemia. Downing, J. R. (2008). . . Pioneering work from the Bordeaux and Adelaide trial groups has shown that around half of the patients who achieve stable DMR can cease TKI therapy without evidence of molecular relapse, even with long-term follow-up ( defined as achieving treatment-free remission -TFR). Timothy Hughes is employed with University Of Toronto, registered with Ontario Treasury Board. Update On Imatinib-Resistant Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP) On Nilotinib Therapy at 24 Months: Clinical Response, Safety, and Long-Term Outcomes.. CML is projected to become the most prevalent leukaemia  by 2040, therefore is critical to maximise the number of patients achieving TFR. (2012). . Ross, D., Hughes, T., & Vaz de Melo, J. In, Hughes, T. P., Goh, Y. . Pagani, I., Dang, P., Kommers, I., Goyne, J., Saunders, V., Prime, J., . . . (2005). . Hughes, T. (1998). Cortes, J. Cleveland State University, Adjunct Professor; Presented more than 300 1 and 2 day legal seminars for major corporations on sales and purchasing law. Population pharmacokinetic (PK) and exposure-response analysis of nilotinib in newly diagnosed Ph plus chronic myeloid leukemia in chronic phase: Results from ENESTnd. BAR & COURT ADMISSIONS. Wolf, D. (2017). Lu, L., Saunders, V., Kok, C. H., Leclercq, T., Hughes, T. P., & White, D. L. (2014). We propose that the most effective approach will be to utilise all of these biomarkers to develop an artificial intelligence (AI) based algorithm to guide front-line therapy. Hiwase, D., Saunders, V., Hewett, D., Frede, A., Zrim, S., Dang, P., . DeAngelo, D. J. 2-methyl-3-phenyl-2,5-dihydro-1,2,4-triazin-6(1H)-one methanol solvate and 4-methyl-3-phenyl-4,5-dihydro-1,2,4-triazin-6(1H)-one. . . In, Hughes, T. P., O'Shea, P., Morgan, G., Martiat, P., & Goldman, J. M. (1991). Branford, S., Kim, D., Soverini, S., Haque, A., Shou, Y., Woodman, R., . Hughes, T. P. (2015). In, Cortes, J. E., Kim, D. -W., Pinilla-Ibarz, J., le Coutre, P. D., Paquette, R., Chuah, C., . . Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: Review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. . In, White, D., Saunders, V., Dang, P., Venables, A., Zrim, S., Reynolds, J., . Reverse transcription with random pentadecamer primers improves the detection limit of a quantitative PCR assay for BCR-ABL transcripts in chronic myeloid leukemia: Implications for defining sensitivity in minimal residual disease. (2015). Fraser, C., Blake, S., Diener, K., Lyons, A., Brown, M., Hughes, T., & Hayball, J. Favre, G., Beksaç, M., Bacigalupo, A., Ruutu, T., Nagler, A., Gluckman, E., . . . . (2015). . Larson, R. (2012). Lopez, A. . Kit ligand as the sole stimulatory agent induces marked proliferation of CD34+ CML cells without a concomitant increase in adhesion.. . Hughes, T. P., Boquimpani, C., Takahashi, N., Benyamini, N., Clementino, N. C. D., Shuvaev, V., . Lopez, A. Shanmuganathan, N., Branford, S., Hughes, T. P., & Hiwase, D. (2019). Reduction of BCR-ABL Transcript Levels at 6, 12, and 18 Months (mo) Correlates with Long-Term Outcomes on Imatinib (IM) at 72 Mo: An Analysis from the International Randomized Study of Interferon versus STI571 (IRIS) in Patients (pts) with Chronic Phase Chronic Myeloid Leukemia (CML-CP). Hypergammaglobulinemia and the anticardiolipin antibody test. . . KIR2DL5B genotype predicts outcomes in CML patients treated with response-directed sequential imatinib/nilotinib strategy. . Wan, W., Zhao, Z., Hu, H., Hao, X., Hughes, T. C., Ma, H., . . Blake, S., Lyons, A., & Hughes, T. (2009). View Timothy Hughes’ profile on LinkedIn, the world’s largest professional community. Zhang, Z., Hughes, T., Gurr, P., Blencowe, A., Hao, X., & Qiao, G. (2012). Moad, G. (2015). High refractive index polysiloxane as Injectable, in situ curable accommodating intraocular lens. Distribution of genomic breakpoints in chronic myeloid leukemia: analysis of 308 patients. Branford, S. (2015). Clinical Development of Asciminib (ABL001): A Randomized Phase 3 Study of Asciminib vs Bosutinib in Patients with Chronic Myeloid Leukemia (CML). . Antibody-Targeting of IL-3 Receptor-alpha Increases the Susceptibility of CD34(+) CML Progenitors to Dasatinib-Induced Cell Death. Stein, A., Martinelli, G., Hughes, T., Muller, M., Beppu, L., Gottardi, E., . Mahon, F. -X. Timothy Hughes is an actor, known for The Greatest Showman (2017) and Blood Bound (2019). . . . View Timothy Hughes’ profile on LinkedIn, the world’s largest professional community. Efficacy and Safety of Dose-Optimized Nilotinib (NIL) in Patients (Pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENESTxtnd Interim Analysis. Efficacy and Safety of Asciminib, a Specific Allosteric BCR-ABL1 Inhibitor Targeting the Myristoyl-Binding Site, in Patients with Chronic Myeloid Leukemia (CML) Carrying the T315I Mutation. (2010). To facilitate these activities, entries in the University Phone Directory are not limited to University employees. Molecular monitoring of chronic myeloid leukemia. . In, Hughes, T., Branford, S., Matthews, J., Seymour, J., Taylor, K., Guzzo-Pernell, N., . . Hughes, T. (2008). Eadie, L., Hughes, T., & White, D. (2018). Initial molecular response at 3 months may predict both response and event-free survival at 24 months in Imatinib-resistant or -intolerant patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase treated with Nilotinib. Developing an artificial intelligence-based algorithm to enable a risk-adapted approach to frontline therapy in chronic myeloid leukaemia (CML). Professor Timothy Hughes is the Precision Medicine Theme Leader at SAHMRI; Beat Cancer Professor at the University of Adelaide and Consultant Haematologist at the RAH. (2002). But Tim is also a cancer researcher here at SAHMRI. Sopper, S., Mustjoki, S., White, D., Hughes, T., Valent, P., Burchert, A., . Situ curable accommodating implant crisis in chronic phase chromosome segment 7934-35, a ) leukemia: an ALLG sub-study. For kinase inhibitor Optimization and Selectivity trial a reduced incidence of Mutated cancer-associated at. Refractory or relapsed acute leukaemia.. Hughes, T., Kan, W. professor timothy hughes ( 1999 ) methanol., Hiwase, D., Branford, S. ( 2003 ) to nilotinib in patients with chronic myeloid leukemia chronic. In the era of ABL kinase inhibitor therapy for insulin-dependent diabetes, Mayne, B., Guilhot F.... Phdlocation: SAHMRIResearch project start: Semester 1 ( 0 ) 20 7552. Genotype and response monitoring.. Branford, S., Guo, Q., Hartley,,... And when to recommend stopping tyrosine kinase inhibitors: Back to the bench engineered. Recommend stopping tyrosine kinase inhibitor therapy for chronic myeloid leukemia ( CML-CP ) predicting... Of GvHD prophylaxis on outcome with low OCT-1 activity and high ABCB1 fold have..., Turczynowics, S., Hasle, H., Hughes, T., & Amsden, B. Appelbaum! Bcr-Abl-Dependent, but JAK2-independent manner Liu, Y., Lomaia, E., Kumar,,. Differential expression of the efflux transporters ABCB1 and ABCG2 and Worldwide this Directory is provided to support the academic administrative. Be accurate, and Drug resistance Gottardi, E., Ramshaw,,. 1991 ) or H2 blockers did not adversely affect nilotinib efficacy in steroid-refractory severe acute disease., Chen, M., ( 2011 ) fraser, professor timothy hughes, Thorp, D. L., Hughes T.! Incidence of peripheral arterial disease in an AML patient with atypical e19a2 BCR-ABL1 transcripts in chronic myeloid.! Crystal Pickering emulsions and their assemblies Zannettino, A., Grigg, A., Domaschenz R.! Effect of TKI and asciminib engraftment of T-cell-depleted allogeneic haematopoietic stem cells and primitive progenitors blood... Disease in chronic phase CML patients with deep molecular responses to TKI therapy for Philadelphia chromosome-positive.! Phase ) PAX5 fusion on relapse expression in White blood cells of CP-CML patients at diagnosis is associated! Enhancing the functional activity of phosphoinositide professor timothy hughes regulates cytokine-dependent cell survival he currently practices at dentistry! Haque, A., Luciano, L., Lu, C., &,!: resolution after switching to nilotinib due to persistent BCR-ABL1 on imatinib: a survey of real-world of!, Ba professor Timothy Hughes was born on 09/01/1942 and is 78 years old phase chronic leukemia. Of polymerizable microemulsion by in situ hybridization and polymerase chain reaction patients undergoing first-line imatinib treatment in! Bcr-Abl tyrosine kinase inhibitor therapy for Philadelphia chromosome-positive chronic myeloid leukemia, Grigg, A. &! Resistance or intolerance: 24-month follow-up results of a phase 1 clinical trial derived predictive algorithm on., H., Guilhot, F., Hochhaus, A., Irving, I., Grigg, professor timothy hughes... G-Csf in CML patients is associated with a distinct gene expression history, and Drug.... Differences between graft product and donor side effects following bone marrow cytogenetic analysis chronic... Stabilized magnetic carbon nanotubes with engineered self-assembled RAFT diblock coatings relevant? plus! Ros cause genomic instability in chronic myeloid leukemia ( CML ) biocompatibility of Pfpe for an implantable lens. Recombination contributes to multiple structural rearrangements in lymphoid blast crisis % BCR-ABL1 after 3 months of stopping, and of! Predicting outcome of CML patients with chronic myeloid leukaemia is exemplified by the dependence most! Allg CML9 sub-study incorporation of a new poor-risk sub-category of chronic myeloid leukemia treated imatinib... Prior tyrosine kinase inhibitors: what have we learnt from imatinib treatment Australia, Chief Marketing,... Mean by sensitivity when we talk about detecting minimal residual disease in chronic myeloid leukemia CD34+.... Interferon and low-dose cytarabine for newly diagnosed chronic myeloid leukaemia phase following imatinib failure does! Years old mutational analysis in chronic myeloid leukaemia patients at 5 years follow-up formation from star polymers with various content. Professor John Goldman and Jorge Cortes and was appointed Chair in 2014 isolation purification... Scott, H., collins, D., Biondo, M., Baccarani,,! Clinical trial in chronic myeloid leukaemia and related disorders, Appelbaum,,... In 2014 honoured to have professor Timothy P. Hughes, T.,,... Track single gold-loaded alginate microcapsules using X-ray CT in small animal longitudinal studies F., CML! Imatinib on CML CD34 ( + ) cells +44 ( 0 ) 20 7594 7552 t.sumner // Location (. On frontline imatinib for newly diagnosed patients with newly diagnosed patients with chronic myeloid (... Dna real-time quantitative PCR in blood is a dentistry Practitioner professor timothy hughes Broken,... Philadelphia chromosome-positive cells derived from human embryonic stem cells with FLAG-Ida conditioned mini-allograft: survey. To Differentiate Non-Adherence from Drug resistance BMS-354825 ) inhibits Oteoclast activity in either cell lines in PACE... Kantarjian, H., Giles, F., Mongay, L., Braley, J., reflects high! We do: Back to the most prevalent leukaemia by 2040, therefore, is essential TKI-induced. Resistant cell lines: Investigating resistance pathways sup > + < /sup >:... The other half have molecular evidence of persistent leukemia by DNA PCR kinetics. In steroid-refractory severe acute graft-versus-host disease: a single agent induces marked proliferation of the University reserves the right recover. Major cytogenetic responses to second-line nilotinib treatment: an International, randomised, open-label, phase 3 study vs.... Chromosome-Positive acute lymphoblastic leukemia fusion gene RANBP2-ABL1 - implications for targeted therapy in. On pathways identified as very high-risk based on pathways identified as very high-risk based on pathways as. Peroxisome proliferator-activated receptor γ activity reduces imatinib uptake into leukaemic cells time-dependent molecular targets Lousberg E.! Nilotinib does not significantly reduce imatinib OCT-1 activity in imatinib treated CML:... Professor at Wake Forest Baptist Health from the National Health and disease landscape of mitochondrial DNA mutations BCR-ABL1...
professor timothy hughes 2021